plasma GH response to glucose load and TRH administration were abnormal before the operation, and became normal thereafter. The somatostatin analogue SMS 201\x=req-\ 995 was found to be a potent inhibitor of the ectopic GHRH and the GH secretion (>500 to 42 ng/l and 15.4 \g=m\g/l to 0.8 \g=m\g/l ,respectively). The Ectopic secretion of growth hormone-releasing hormone is a rare cause of acromegaly, which may underlie the disease in 1-2% of all cases (1, 2) . The most common tumours secreting GHRH are bron¬ chial carcinoids and pancreatic islet cell tumours (3) . Differential Somatostatin determination was performed using ma¬ terials provided by Incstar (Minnesota, USA) as previ¬ ously described (5) . The sensitivity of the assay is 8 ng/1 and all the samples were determined in the same assay.
IGF-I in serum was measured by RIA using a kit (Inc¬ star, USA) by a previously described protocol (6) .
Plasma GH, PRL and insulin levels were determined by 
Results
Basal hormone levels Table 1 shows basal GHRH, GH, IGF-I and PRL levels at different stages before and after the op¬ eration.
Plasma GHRH levels were very high in repeated determinations before the operation. They de¬ creased to 72 ng/1 as early as at the end of the operation, and became normal one week later.
Normal levels were also found one year later.
Basal GH levels were consistently high before the operation, and also decreased to near normal levels at the end of the operation and one week later. Levels at two weeks and one year after the opera¬ tion were within normal limits.
IGF-I levels measured before the operation were high and returned to normal levels one year later.
Plasma PRL levels were also elevated before the operation, and slowly decreased thereafter, being still significantly elevated two weeks after the op¬ eration, bur normal after a year.
Stimulation tests
Oral glucose load had no suppressive effect on the high GH levels before the operation, but it sup¬ pressed GH levels two weeks following the opera¬ tion (from 3.8 to 1.9 pg/1).
TRH test (Fig. 1) revealed a marked GH stimu- (1, 19) .
The finding that acute administration of soma¬ tostatin to our patient induced a dramatic longlasting suppression of both GH and GHRH is con¬ sistent with other reported cases of ectopic GHRH, where somatostatin had a dual effect, both GHRH suppression and a direct effect on GH secretion (8) (9) (10) 13, 14, 20, 21) . By studying the tumour in a monolayer tissue culture, we proved for the first time that the effect of somatostatin on plasma GHRH is mediated by a direct immediate action on the GHRH-secreting cells of the tumour. The mechanism underlying this direct action is yet to be determined.
Whereas plasma immunoreactive GHRH was found to increase slightly following meals in healthy normal subjects (22, 23) , in our patient, there was a dramatic suppression of GHRH follow¬ ing a mixed meal, which was not accompanied by a parallel decrease in GH. The mechanism whereby the decrease in GHRH occurs is not known, but the finding that plasma somatostatin increased after a mixed meal in our patient, as was also reported in healthy and diabetic subjects (23, 24) , suggests a role for peripheral somatostatin in the decreased plasma GHRH level. The lack of a parallel decrease in plasma GH is consistent with other reports show¬ ing dissociation between plasma GHRH and pitu¬ itary GH secretion (25) , as well as with the para¬ doxical response of GH to glucose elevation in these cases (8, 9 
